Ameritas Investment Partners Inc. raised its holdings in shares of Radius Health, Inc. (NASDAQ:RDUS) by 19.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,266 shares of the biopharmaceutical company’s stock after acquiring an additional 541 shares during the period. Ameritas Investment Partners Inc.’s holdings in Radius Health were worth $148,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also modified their holdings of RDUS. BlackRock Inc. grew its position in Radius Health by 98,245.6% during the first quarter. BlackRock Inc. now owns 2,630,745 shares of the biopharmaceutical company’s stock valued at $101,679,000 after acquiring an additional 2,628,070 shares during the last quarter. Farallon Capital Management LLC grew its position in Radius Health by 18.3% during the second quarter. Farallon Capital Management LLC now owns 3,686,300 shares of the biopharmaceutical company’s stock valued at $166,731,000 after acquiring an additional 569,300 shares during the last quarter. TimesSquare Capital Management LLC bought a new position in Radius Health during the second quarter valued at approximately $25,589,000. BB Biotech AG grew its position in Radius Health by 11.0% during the second quarter. BB Biotech AG now owns 5,038,799 shares of the biopharmaceutical company’s stock valued at $227,905,000 after acquiring an additional 498,400 shares during the last quarter. Finally, RA Capital Management LLC bought a new position in Radius Health during the second quarter valued at approximately $22,486,000.
TRADEMARK VIOLATION WARNING: “Ameritas Investment Partners Inc. Acquires 541 Shares of Radius Health, Inc. (RDUS)” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this story on another website, it was illegally stolen and reposted in violation of US and international copyright legislation. The correct version of this story can be accessed at https://www.com-unik.info/2017/11/06/ameritas-investment-partners-inc-acquires-541-shares-of-radius-health-inc-rdus.html.
Radius Health, Inc. (NASDAQ:RDUS) opened at $29.56 on Monday. The company has a current ratio of 12.87, a quick ratio of 12.79 and a debt-to-equity ratio of 0.53. Radius Health, Inc. has a fifty-two week low of $27.16 and a fifty-two week high of $55.97.
Radius Health (NASDAQ:RDUS) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.03). The firm had revenue of $13.50 million for the quarter, compared to analysts’ expectations of $6.90 million. During the same quarter last year, the company earned ($1.07) EPS. sell-side analysts expect that Radius Health, Inc. will post -5.28 EPS for the current year.
A number of brokerages have commented on RDUS. BidaskClub cut shares of Radius Health from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. Cantor Fitzgerald set a $65.00 price target on shares of Radius Health and gave the company a “buy” rating in a research report on Monday, July 17th. Canaccord Genuity set a $85.00 price target on shares of Radius Health and gave the company a “buy” rating in a research report on Monday, July 17th. Zacks Investment Research upgraded shares of Radius Health from a “sell” rating to a “hold” rating in a research report on Tuesday, August 8th. Finally, Maxim Group reiterated a “positive” rating on shares of Radius Health in a research report on Friday, September 29th. They noted that the move was a valuation call. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and five have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $51.00.
In other news, insider Jesper Hoiland bought 6,100 shares of the business’s stock in a transaction dated Friday, September 15th. The shares were purchased at an average price of $32.72 per share, for a total transaction of $199,592.00. Following the completion of the acquisition, the insider now owns 6,100 shares of the company’s stock, valued at $199,592. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Growth N. V. Biotech bought 60,000 shares of the business’s stock in a transaction dated Wednesday, August 16th. The stock was purchased at an average price of $35.98 per share, for a total transaction of $2,158,800.00. Following the acquisition, the insider now directly owns 5,248,799 shares of the company’s stock, valued at approximately $188,851,788.02. The disclosure for this purchase can be found here. Insiders bought 519,100 shares of company stock worth $17,970,882 in the last 90 days. Company insiders own 15.00% of the company’s stock.
Radius Health Company Profile
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
What are top analysts saying about Radius Health Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Radius Health Inc. and related companies.